Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Boukichou-Abdelkader, Nisa (57216392995)"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Reduction in the Risk of Peripheral Neuropathy and Lower Decrease in Kidney Function with Metformin, Linagliptin or Their Fixed-Dose Combination Compared to Placebo in Prediabetes: A Randomized Controlled Trial
    (2023)
    Gabriel, Rafael (7103316027)
    ;
    Boukichou-Abdelkader, Nisa (57216392995)
    ;
    Gilis-Januszewska, Aleksandra (7801318789)
    ;
    Makrilakis, Konstantinos (6603246389)
    ;
    Gómez-Huelgas, Ricardo (7004734060)
    ;
    Kamenov, Zdravko (6603678114)
    ;
    Paulweber, Bernhard (36519500600)
    ;
    Satman, Ilhan (6603732754)
    ;
    Djordjevic, Predrag (57200124383)
    ;
    Alkandari, Abdullah (56182455000)
    ;
    Mitrakou, Asimina (7004179428)
    ;
    Lalic, Nebojsa (13702597500)
    ;
    Egido, Jesús (35463099300)
    ;
    Más-Fontao, Sebastián (6701721229)
    ;
    Calvet, Jean Henri (37664688100)
    ;
    Pastor, José Carlos (56871286300)
    ;
    Lindström, Jaana (55646081100)
    ;
    Lind, Marcus (13402929500)
    ;
    Acosta, Tania (36518089000)
    ;
    Silva, Luis (57216391876)
    ;
    Tuomilehto, Jaakko (36012823000)
    Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo. © 2023 by the authors.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback